SLC9A1 and prostate cancer: NHE-1 is usually highly expressed in prostate cancers and correlates with the expression of transcription factors, such as Zeb1, which promote the mesenchymal transition and, consequently, the invasion and metastatic potential of the tumor lesions [48].